Lung Cancer News

It took more than 35 years for tumor-infiltrating lymphocytes, which Steven A. Rosenberg, MD, PhD, and colleagues first reported on in 1988 for the treatment of advanced melanoma, to progress enough to gain FDA approval.

The FDA approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer following tumor resection and detection by an FDA-approved test.

Use of immune checkpoint inhibitors for pregnant women with cancer may be safer than previously thought, according to study results published in JAMA Network Open.

In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more.

Durvalumab extended OS and PFS compared with placebo for patients with limited-stage small cell lung cancer, according to topline data released by the agent’s manufacturer.

Most adults have not tested their homes for radon, nor have they taken action to reduce radon exposure despite its link to cancer, a survey showed.

The FDA granted fast track designation to PT217, a novel bispecific antibody, for the treatment of adults with extensive-stage small cell lung cancer, according to a release from the manufacturer.

Individuals with cancer reported significantly reduced pain immediately following a 10-minute virtual reality (VR) session, study results published in Cancer showed.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for the treatment of adults with unresectable or metastatic HER2-positive solid tumors who received previous systemic therapy and lack additional treatment options.

Fewer than one-third of recently approved molecular-targeted cancer therapies demonstrated “substantial patient benefits,” according to data published in JAMA Oncology.